In most cases, the safety of novel strains has been
deduced mainly from the common occurrence of the species
either in foods or as normal commensals in the human gut.
With the notable exception of enterococci, lactic acid
bacteria together with bifidobacteria have only rarely been
associated with human clinical infections (mainly bacteraemia
and myocarditis in patients with a severe underlying
disease) [10, 11]